Image courtesy of Shutterstock
Results of the Wellcome Trust funded trial of the experimental anti-Ebola drug TKM-130803 have been published today in PLOS Medicine. Using a novel approach designed to get rapid indications of a drug's effectiveness, the trial showed that at the dose given the drug did not improve survival compared to historic controls.
TKM-130803 interferes with the production of two essential Ebola virus proteins and has been shown to improve survival when given to monkeys experimentally infected with Ebola virus. Scientists from the University of Oxford and Sierra Leone worked with the humanitarian organisation GOAL Global, the World Health Organization, and collaborators from a number of other institutions to test whether TKM-130803 could improve survival in adults with Ebola infection.